BPC-157 side effects and risks

Reported side effects

• Headache and gas: Most frequent events in the enema phase 1 abstract; rates were not reported. No obvious placebo difference., mild (source)
• Injection-site redness or swelling: One FDA injection report described nine days of redness and swelling; another peptide was also used., moderate. Seek review if worsening, hot or painful, or accompanied by fever. (source)
• Shortness of breath: One FDA report led to an emergency visit. Timing and other medicines were not detailed., serious. Stop use and seek urgent care; causality is not established. (source)
• Skin or gum darkening with a blend: One BPC 157/TB 500 report recurred after restarting. The responsible ingredient is unknown., moderate. Stop the blend and have the change assessed. (source)
• Anxiety or loss of pleasure: Forum reports only; no denominator or proven cause., moderate. Stop use and seek assessment for new or persistent mood changes. (source)
• Nausea, fatigue or stomach upset: Oral users describe these symptoms; rates and product contents are unknown., mild. Review persistent symptoms; do not assume they show healing or detox. (source)
• Nasal dryness or postnasal drip: Reported by a nasal blend user; no incidence estimate., mild (source)

Stop and get help if

• Trouble breathing, throat swelling, collapse or fainting after a dose: Stop use and call emergency services now.
• Fever with a hot, spreading injection-site reaction, confusion or very fast breathing: Seek urgent care now; call emergency services for confusion or breathing trouble.
• New chest pain, severe palpitations or sudden vision loss: Stop use and get urgent medical assessment.
• New severe depression or thoughts of self-harm: Stop use and seek urgent mental-health help; use emergency services if there is immediate danger.

Who should avoid it

• pregnant: No human pregnancy safety data. Block as a precaution; animal findings do not establish fetal safety.
• breastfeeding: No human milk-transfer or infant safety data. Block as a precaution.
• tryingToConceive: No adequate human fertility or early-pregnancy safety data. Block as a precaution.
• under18: No pediatric dose or safety study found. Block use in minors.
• activeCancer: Lab studies promote blood-vessel growth. Block as a precaution; cancer promotion in humans has not been established.
• cancerHistory: Blood-vessel growth raises a theoretical concern. Review cancer history with the treating team; recurrence risk is unknown.
• other: Avoid a product that previously caused a severe allergic reaction; impurities and inactive ingredients can matter.
• kidneyDisease: Human exposure and clearance in kidney disease are unknown; the two-person IV pilot cannot settle this.
• liverDisease: No dosing or safety study in people with liver disease was found.
• heartCondition: Human artery tissue relaxed in the lab. Whole-body blood-pressure and heart effects remain uncertain.
• uncontrolledBloodPressure: Effects on blood pressure are not established in patients. The vessel-signaling findings warrant review.
• bleedingDisorder: Needle procedures can cause bruising or bleeding; BPC-157 effects on human clotting are unknown.
• psychiatricCondition: Users report anxiety, low mood and loss of pleasure. Causality and frequency are unknown.
• surgeryPlanned: Tell the surgical team about use and blends. There is no validated preoperative stopping interval.
• testedAthlete: WADA 2026 explicitly prohibits BPC-157 at all times under S0, including outside competition.

Interactions

• Anticoagulants and antiplatelet medicines: Needle procedures can increase bruising or bleeding. A direct BPC-157 drug interaction has not been measured.
• Blood-pressure medicines, nitrates and PDE5 inhibitors: Additive low blood pressure is theoretical from artery-tissue relaxation. No clinical interaction study confirms it.
• TB-500 and other experimental repair peptides: Human safety of these stacks is unknown. A blend-related FDA report cannot identify the responsible peptide.
• Insulin and sulfonylureas: No BPC-specific low-blood-sugar interaction is established. Normal glucose in two IV users cannot exclude an interaction.

Product quality risks

• A 2026 preprint found 17 BPC-157 test reports without the stated peptide, a reported identity-failure rate of 3.5%.
• That preprint found median BPC-157 content of 103.50% of label, IQR 94.20%-115.10%; the samples were not a random market survey.
• Across all peptides, 15% of 243 endotoxin-tested samples had measurable endotoxin; this is not a BPC-specific rate.
• FDA identifies peptide impurities, aggregates and unclear ingredient identity as safety concerns.
• Health Canada seized unauthorized BPC-157 injections and recalled unauthorized raw powder; these actions do not measure every vial.
• FDA issued an October 23, 2020 warning about BPC-157 products with COVID-19 claims; corrective status did not mean approval.